Insmed (INSM) Gets New Composition Matter U.S. Patent for ARIKACE
Tweet Send to a Friend
Up)
Insmed Incorporated (Nasdaq: INSM), announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent for ARIKACE® (liposomal amikacin for inhalation), U.S. Patent No. 8,226,975. Amikacin is one of the aminoglycosides covered by the patent. The patent describes a system for treating or providing prophylaxis against pulmonary infections, and includes both of the compound's lead indications, cystic fibrosis (CF) patients who have Pseudomonas lung infections and patients who have non-TB Mycobacteria (NTM) lung infections.
The patent claims a new and unique inhaled treatment system and formulation in which the aerosol delivered to the lung contains a combination of both free unencapsulated aminoglycoside drug that is present outside the liposomes and aminoglycoside drug encapsulated inside liposomes. When delivered, ARIKACE contains both the free and liposomal encapsulated amikacin, which could be beneficial to patients in two ways. The delivery of free amikacin provides immediate bactericidal activity against the initial load of organisms, and the liposome encapsulated amikacin provides sustained bactericidal activity against persistent organisms.
The new patent provides exclusivity at least through May 18, 2027.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The patent claims a new and unique inhaled treatment system and formulation in which the aerosol delivered to the lung contains a combination of both free unencapsulated aminoglycoside drug that is present outside the liposomes and aminoglycoside drug encapsulated inside liposomes. When delivered, ARIKACE contains both the free and liposomal encapsulated amikacin, which could be beneficial to patients in two ways. The delivery of free amikacin provides immediate bactericidal activity against the initial load of organisms, and the liposome encapsulated amikacin provides sustained bactericidal activity against persistent organisms.
The new patent provides exclusivity at least through May 18, 2027.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
- Lazard Capital Starts Insmed (INSM) at Buy
- Unusual 11 Mid-Day Movers 05/15: (MFLR) (CHCI) (NYNY) Higher; (SVNT) (XONE) (WTT) Lower
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
